人乳头瘤病毒 (HPV) 与口咽鳞状细胞癌 (OPSCC) 有因果关系。血浆肿瘤组织修饰病毒 (TTMV)-HPV DNA 检测已成为治疗后监测以确定复发性疾病的生物标志物策略。我们的目的是了解 TTMV-HPV DNA 在监测患有复发性或转移性 (R/M) HPV OPSCC 的患者时的预后和预测潜力。 这项回顾性观察队列研究包括来自 4 个学术中心的 80 名患有 R/M HPV OPSCC 的患者，如果他们在 R/M 疾病过程中的任何时间点进行了 ≥ 1 次血浆 TTMV-HPV DNA 检测。医生报告的临床数据和治疗历史以及研究者评估的治疗反应和生存率都被记录在中央数据库中。描述性统计和非参数关联检验与生存分析（Kaplan-Meier 方法）一起使用。随着时间的推移，十六名 (20%) 患者有 ≥ 5 个测试结果。连续 TTMV-HPV DNA 检测的中间间隔为 73 天。随着每名患者转移部位数量的增加，中位 TTMV-HPV DNA 评分越高（<2 vs. 2；p < 0.01）。随着时间的推移，评分变化受到 R/M 治疗方式的影响，并且在对 R/M 治疗完全缓解的患者中，67% (12/18) 的评分变化无法检测到。与未检测到分数的患者相比，上次随访时分数可检测到的患者的生存率明显较差（对数秩检验，p < 0.01）。TTMV-HPV DNA 似乎可作为监测 R/M 治疗反应的预后工具。环境。未来，TTMV-HPV DNA 可以作为转移环境中的探索性临床试验终点进行探索。版权所有 © 2024 Elsevier Ltd。保留所有权利。

Human papillomavirus (HPV) is causally linked to oropharyngeal squamous cell carcinoma (OPSCC). Testing for plasma tumor tissue modified viral (TTMV)-HPV DNA has emerged as a biomarker strategy for post-treatment surveillance to identify recurrent disease. We aimed to understand the prognostic and predictive potential of TTMV-HPV DNA when monitoring patients who had developed recurrent or metastatic (R/M) HPV+OPSCC.This retrospective observational cohort study included 80 patients from 4 academic centers with R/M HPV+OPSCC if they had ≥ 1 plasma TTMV-HPV DNA test obtained at any point during their R/M disease course. Physician-reported clinical data and treatment history were captured in a centralized database, along with investigator-assessed response to therapy and survival. Descriptive statistics and non-parametric tests of association were employed along with survival analyses (Kaplan-Meier method).Sixteen (20 %) patients had ≥ 5 test results over time. Consecutive TTMV-HPV DNA tests were performed a median of 73 days apart. Median TTMV-HPV DNA scores were higher with an increasing per-patient number of metastatic sites (<2 vs. 2+; p < 0.01). Score changes over time were influenced by R/M treatment modality and became undetectable in 67 % (12/18) of patients who achieved a complete response to R/M therapy. Patients with detectable scores at last follow-up had significantly worse survival compared with those who were undetectable (log-rank test, p < 0.01).TTMV-HPV DNA appears useful as a prognostic tool for monitoring response to therapy in the R/M setting. In the future, TTMV-HPV DNA could be explored as an exploratory clinical trial endpoint in the metastatic setting.Copyright © 2024 Elsevier Ltd. All rights reserved.